The Incretin Effect Explained: Why GLP-1 Drugs Work

The incretin effect is one of the most important discoveries in metabolism — and it's the physiology that modern weight and diabetes drugs are engineered to harness. Here's the core observation: if you swallow glucose, your body releases far more insulin than if the identical amount of glucose is dripped into a vein to reach the same blood-sugar level. The difference is huge — gut-derived hormones account for the majority of the insulin response to an oral meal in healthy people (Nauck & Meier 2016 ^[2]). Those gut hormones are called incretins, and the two main ones are GLP-1 and GIP (Baggio & Drucker 2007 ^[3]). When you eat, the gut senses nutrients and releases these hormones, which travel to the pancreas and tell it to make more insulin — but only when blood glucose is actually rising. That “only when needed” design is why it's called glucose-dependent. Drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) work by amplifying this exact system.

The honest summary

• The incretin effect = gut hormones amplifying insulin after you eat. Oral glucose triggers a much larger insulin response than IV glucose at the same blood level, because the gut releases hormones that prime the pancreas (Nauck & Meier 2016^[2]).
• The two incretin hormones are GLP-1 and GIP. GLP-1 (glucagon-like peptide-1) is made mainly by L-cells in the lower small intestine and colon; GIP (glucose-dependent insulinotropic polypeptide) is made by K-cells in the upper small intestine (Baggio & Drucker 2007^[3]).
• It's glucose-dependent. Incretins boost insulin chiefly when blood glucose is elevated. When sugar is normal or low, the signal fades — which is why incretin-based drugs carry little hypoglycemia risk on their own (Drucker 2018^[4]).
• The incretin effect is blunted in type 2 diabetes. Nauck's landmark 1986 study showed people with type 2 diabetes lose much of this gut-driven insulin amplification (Nauck 1986^[1]).
• Modern drugs rebuild and amplify the system. GLP-1 receptor agonists supercharge the GLP-1 arm; tirzepatide is a dual agonist that also activates the GIP receptor (Coskun 2018^[6]). GLP-1 also slows the stomach and curbs appetite — which is why these drugs drive weight loss, not just glucose control (Drucker 2018^[4]).

What the incretin effect actually is

Picture two identical doses of glucose. One you drink; the other is infused into a vein so carefully that your blood-sugar curve matches the oral one exactly. Logically, the same blood glucose should drive the same insulin. It doesn't. The oral route produces a much bigger insulin surge — and that gap, the “extra” insulin that only appears when glucose passes through the gut, is the incretin effect. In healthy people it's responsible for a large share — often cited at roughly half to two-thirds — of the total insulin secreted after an oral glucose load (Nauck & Meier 2016^[2]). The mechanism: nutrients in the gut lumen stimulate specialized hormone-secreting cells, which release incretin hormones into the bloodstream; those hormones reach the pancreatic beta cells and amplify insulin output (Baggio & Drucker 2007^[3]).

The two incretin hormones: GLP-1 and GIP

There are two principal incretin hormones, and they're made in different parts of the gut. GIP — glucose-dependent insulinotropic polypeptide — is secreted by K-cells, concentrated in the upper small intestine (duodenum and jejunum). GLP-1 — glucagon-like peptide-1 — is secreted by L-cells, which are densest in the lower small intestine (ileum) and colon (Baggio & Drucker 2007^[3]). Both are released within minutes of eating and both stimulate glucose-dependent insulin secretion, but GLP-1 has a broader job description: it also slows gastric emptying and acts on the brain to promote satiety (Drucker 2018^[4]; McLean 2021^[5]). For a deeper look at the GIP side specifically, see our GIP receptor explainer.

The blunted incretin effect in type 2 diabetes

In 1986, Michael Nauck and colleagues published the foundational observation in Diabetologia: people with type 2 diabetes have a markedly reduced incretin effect (Nauck 1986^[1]). Comparing the insulin response to oral versus isoglycemic IV glucose, they found that the gut-driven amplification that dominates in healthy people is substantially diminished in type 2 diabetes. That deficit became a central target: if the natural gut-hormone signal is impaired, could replacing or amplifying it restore better glucose control? Later work clarified that in type 2 diabetes the GIP arm becomes relatively ineffective at the beta cell, while the GLP-1 arm — though its levels may be modestly reduced — still works when GLP-1 is supplied at higher (pharmacologic) doses (Nauck & Meier 2016^[2]). That single insight is the bridge from physiology to medicine.

How incretin-based drugs harness it

Native GLP-1 is destroyed within a couple of minutes by an enzyme (DPP-4), so the body's own hormone can't be used as a drug directly. Pharmaceutical chemists solved this by engineering long-acting GLP-1 receptor agonists — molecules that resist degradation and keep activating the GLP-1 receptor for days. These drugs amplify the GLP-1 arm of the incretin system far beyond what a meal produces: more glucose-dependent insulin, less glucagon, slower gastric emptying, and a strong brain-mediated reduction in appetite (Drucker 2018^[4]; McLean 2021^[5]). Semaglutide — sold as Ozempic for diabetes and Wegovy for weight loss — is the best-known example.

Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) goes a step further. It is a dual agonist — a single molecule that activates both the GIP receptor and the GLP-1 receptor (Coskun 2018^[6]). The idea is to engage both incretin pathways at once. In a head-to-head trial against semaglutide in type 2 diabetes (SURPASS-2), tirzepatide produced greater reductions in HbA1c and body weight (Frías 2021^[7]). For how the dual-agonist approach compares to next-generation triple agonists, see our tirzepatide vs. retatrutide mechanism comparison.

Beyond glucose: appetite, the stomach, and weight

The incretin effect was discovered as a glucose-control phenomenon, but GLP-1's reach is wider — which is why these drugs cause weight loss, not merely better blood sugar. GLP-1 slows the rate at which the stomach empties (so meals feel filling for longer) and acts on appetite centers in the brain to reduce hunger and the persistent thoughts about food that many people describe (Drucker 2018^[4]; McLean 2021^[5]). Those central effects are explored in our pieces on the neuroscience of “food noise” and GLP-1 and energy expenditure. The slowed emptying also explains the most common side effect — nausea — and why dosing is titrated up slowly.

Bottom line

The incretin effect is the gut's hormonal amplification of insulin after you eat: oral glucose triggers far more insulin than IV glucose at the same blood level, because intestinal cells release GLP-1 and GIP that prime the pancreas — and they do so glucose-dependently, only when sugar is high (Nauck & Meier 2016^[2]; Baggio & Drucker 2007^[3]). This system is blunted in type 2 diabetes (Nauck 1986^[1]), and the entire class of modern incretin-based medicines — GLP-1 receptor agonists like semaglutide, and the dual GIP/GLP-1 agonist tirzepatide — is engineered to rebuild and amplify it (Drucker 2018^[4]; Coskun 2018^[6]). Understand the incretin effect and you understand why Ozempic, Wegovy, Mounjaro, and Zepbound work the way they do.